Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:IMMP

Prima BioMed Q2 2026 Earnings Report

Prima BioMed logo
$0.42 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$0.42 0.00 (-0.33%)
As of 07/2/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Prima BioMed EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Prima BioMed Revenue Results

Actual Revenue
$1.37 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prima BioMed Announcement Details

Quarter
Q2 2026
Date
1/30/2026
Time
Before Market Opens
Conference Call Date
Wednesday, January 28, 2026
Conference Call Time
6:00PM ET

Upcoming Earnings

Prima BioMed's H2 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 26, 2026 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Prima BioMed's Q2 2026 Press ReleasePress Release

Prima BioMed Earnings Headlines

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
July 2 at 10:10 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321395/0/en/immp-investors-have-opportunity-to-lead-immutep-limited-securities-fraud-lawsuit-with-the-schall-law-firm.html
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
July 2 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-immutep-limited-of-class-action-lawsuit-and-upcoming-deadlines--immp-302815519.html
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
July 5 at 1:00 AM  |  Profits Run (Ad)
IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320706/0/en/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-action-bernstein-liebhard-llp-announces-deadline.html
Prima BioMed (NASDAQ:IMMP) Stock Price Passes Below 50 Day Moving Average - Time to Sell?
July 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30872247
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3320149/1087/en/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-immutep-limited-of-class-action-lawsuit-and-upcoming-deadlines-immp.html
See More Prima BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prima BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prima BioMed and other key companies, straight to your email.

About Prima BioMed

Prima BioMed (NASDAQ:IMMP), trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response. This candidate is being evaluated in multiple Phase II clinical trials across a range of solid tumors, including breast and lung cancers.

Founded in 2001 and headquartered in Sydney, Australia, Prima BioMed has built its expertise in immuno-oncology over two decades of research and development. In 2018, the company rebranded as Immutep to reflect its broader strategic focus on LAG-3–based immunotherapies. Since its inception, Prima BioMed has collaborated with leading academic institutions and cancer centers worldwide to advance its clinical programs and validate the therapeutic potential of LAG-3 modulation.

Prima BioMed maintains a global footprint with additional offices and research partnerships in Europe and the United States. Through collaborations with pharmaceutical partners and contract research organizations, the company aims to accelerate clinical development, streamline regulatory submissions and establish a foundation for potential commercialization. Its pipeline also includes monoclonal antibodies targeting LAG-3 and other immune checkpoints, underscoring a commitment to expanding treatment options for patients with hard-to-treat malignancies.

View Prima BioMed Profile
Earnings Tools